United States· US:40032-700_dc9d6a79-3160-4122-a0d7-139148afe782
SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE
A medicinal product containing sodium sulfate; potassium sulfate; magnesium sulfate anhydrous, registered in United States by Novel Laboratories, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- SODIUM SULFATE; POTASSIUM SULFATE; MAGNESIUM SULFATE ANHYDROUS
- Manufacturer
- Novel Laboratories, Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1140032700832 BOTTLE in 1 CARTON (40032-700-83) / 177 mL in 1 BOTTLE
- ndc1140032-700-83
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sodium sulfate; potassium sulfate; magnesium sulfate anhydrous in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaISOLYTEFresenius Kabi s.r.o., Praha
- FranceIONOVEN, solution pour perfusionFRESENIUS KABI FRANCE
- CanadaISOLYTE S (MULTI-ELECTROLYTE INJECTION)B. BRAUN MEDICAL INC
- IrelandIonolyte solution for infusionFresenius Kabi Deutschland GmbH
- FinlandPlasmalyteBaxter Oy
- IcelandPlasmalyteBaxter Medical AB*
- NorwayPlasmalyteBaxter Medical AB
- United KingdomPotassium chloride 0.15% (potassium 20mmol/1litre) / Magnesium chloride 0.2% (magnesium 10mmol/1litre) / Sodium chloride 0.9% infusion 1litre bagsSpecial Order
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Elonorm, Plasmalyt
- Belgium · Ionolyte, Plasmalyte A Viaflo
- Bulgaria · Плазма-Лайт 148 (Ph 7,4)
- Cyprus · Ionolyte, Plasma-Lyte 148
- Czechia · Isolyte, Plasmalyte
- Denmark · Plasmalyte
- Spain · Ionolyte, Viaflo Plasmalyte 148 (Ph 7,4)
- Finland · Plasmalyte
- France · Ionoven, Plasmalyte Viaflo
- United Kingdom (Northern Ireland) · Ionolyte, Plasma-Lyte 148
- Greece · Ionolyte, Plasma-Lyte 148 (Ph 7,4)
- Croatia · Ionolyte, Plasma-Lyte 148 (Ph 7,4) Viaflo
- Hungary · Isolyte
- Ireland · Ionolyte, Plasma-Lyte 148 (Ph 7.4)
- Iceland · Plasmalyte
- Italy · Crystalsol, Elettrolitica Di Reintegrazione Con Sodio Gluconato
- Lithuania · Plasmalyte
- Luxembourg · Plasmalyte A Viaflo
- Malta · Ionolyte, Plasma-Lyte 148 (Ph 7.4)
- Netherlands · Ionolyte, Plasma-Lyte 148
- Norway · Plasmalyte
- Poland · Plasmalyte, Venolyte
- Portugal · Ionolyte, Plasma-Lyte 148, Viaflo
- Romania · Ionolyte, Plasmalyte
- Sweden · Plasmalyte
- Slovenia · Ionolyte, Plaslyte
- Slovakia · Isolyte, Plasmalyte
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d66df0b7-a67a-4e58-ac72-044479dbe035 GET /v1/drugs/d66df0b7-a67a-4e58-ac72-044479dbe035?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "17.5; 3.13; 1.6",
"substance": "SODIUM SULFATE; POTASSIUM SULFATE; MAGNESIUM SULFATE ANHYDROUS",
"productndc": "40032-700",
"dosage_form": "SOLUTION",
"dea_schedule": null,
"strength_unit": "g/177mL; g/177mL; g/177mL",
"application_number": "ANDA202511",
"marketing_category": "ANDA"
}See everything about sodium sulfate; potassium sulfate; magnesium sulfate anhydrous.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.